Syndax Pharmaceuticals (SNDX) Common Equity (2016 - 2025)
Historic Common Equity for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Q3 2025 value amounting to $115.4 million.
- Syndax Pharmaceuticals' Common Equity fell 6849.89% to $115.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $115.4 million, marking a year-over-year decrease of 6849.89%. This contributed to the annual value of $288.1 million for FY2024, which is 4801.05% down from last year.
- Per Syndax Pharmaceuticals' latest filing, its Common Equity stood at $115.4 million for Q3 2025, which was down 6849.89% from $157.4 million recorded in Q2 2025.
- Syndax Pharmaceuticals' 5-year Common Equity high stood at $554.2 million for Q4 2023, and its period low was $115.4 million during Q3 2025.
- Moreover, its 5-year median value for Common Equity was $361.9 million (2022), whereas its average is $337.4 million.
- In the last 5 years, Syndax Pharmaceuticals' Common Equity soared by 32647.97% in 2021 and then tumbled by 6849.89% in 2025.
- Over the past 5 years, Syndax Pharmaceuticals' Common Equity (Quarter) stood at $408.4 million in 2021, then grew by 14.47% to $467.4 million in 2022, then grew by 18.56% to $554.2 million in 2023, then plummeted by 48.01% to $288.1 million in 2024, then plummeted by 59.94% to $115.4 million in 2025.
- Its Common Equity was $115.4 million in Q3 2025, compared to $157.4 million in Q2 2025 and $215.1 million in Q1 2025.